Group 1 - The core business of the company is the research, production, and sales of mid-to-high-end CNC machine tools, including large machining centers, vertical CNC machines, and horizontal CNC machines [2] - As of March 31, 2025, the company had 11,793 shareholders, a decrease of 431 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The company's latest quarterly report for Q1 2025 shows a revenue of 569 million yuan, a year-on-year increase of 3.80%, and a net profit of 61.36 million yuan, a year-on-year decrease of 11.78%, with a gross profit margin of 21.11% [2] Group 2 - The company's current rolling price-to-earnings (PE) ratio is 19.52, while the average PE ratio for the general equipment industry is 79.52, and the industry median is 41.26, placing the company at the 68th position in the industry ranking [1][3] - The company has received multiple honors, including recognition as a Jiangsu Province Intelligent Manufacturing Factory and a Jiangsu Province Five-Star Cloud Enterprise, among others [2]

Company Overview - Jianfan Biological Technology Group Co., Ltd. specializes in the research, production, and sales of biomaterials and high-tech medical devices [2] - The main products include various blood perfusion devices, dialysis solutions, disinfectants, and blood purification equipment [2] - The company has received multiple accolades, including being recognized as a key high-tech enterprise under the National Torch Program and a national champion in manufacturing [2] Financial Performance - As of Q1 2025, the company reported revenue of 548 million yuan, a year-on-year decrease of 26.40% [2] - The net profit for the same period was 189 million yuan, down 33.71% year-on-year [2] - The gross profit margin stands at 80.74% [2] Market Position - The company's current price-to-earnings (PE) ratio is 23.84, compared to the industry average of 49.46 and the industry median of 36.16 [1][3] - Jianfan Biological ranks 53rd in terms of PE ratio within the medical device industry [1] - The total market capitalization of the company is 17.266 billion yuan [1]

序号股票简称PE(TTM)PE(静)市净率总市值(元)16通源石油44.6642.091.6823.42亿行业平均 26.2430.042.85136.45亿行业中值36.9136.872.7147.51亿1贝肯能源-3245.11418.552.6518.09亿2潜能恒 信-143.68-97.254.7451.36亿3准油股份-73.50-95.4329.0215.02亿4新锦动力-43.20-16.24-11.6526.92亿5惠博 普-19.35-18.021.4734.41亿6海默科技-15.91-15.732.7835.92亿7中曼石油10.1510.941.8779.43亿8海油工程 10.3810.700.86231.24亿9海油发展10.7411.011.45402.54亿10金诚信13.2514.492.46229.42亿11中海油服 18.9420.461.44641.78亿 来源：金融界 最新一期业绩显示，2025年一季报，公司实现营业收入2.58亿元，同比13.21%；净利润78.27万元，同 比-80.38%，销售毛利率22.53%。 5月15日，通源石油今日收盘3.98元，下跌1 ...

最新一期业绩显示，2025年一季报，公司实现营业收入17.36亿元，同比-9.67%；净利润3.79亿元，同 比-21.44%，销售毛利率64.03%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)110乐普医疗147.5985.831.38211.94亿行业平均 49.4645.354.63105.58亿行业中值36.1637.372.5047.48亿1天益医疗-1720.32-2946.711.8421.92亿2澳华内 镜-597.76299.814.7963.00亿3诺唯赞-409.62-484.482.2587.66亿4爱朋医疗-360.69274.024.3429.60亿5博晖 创新-322.93512.443.4547.38亿6硕世生物-134.71-1968.471.2139.40亿7奥精医疗-119.67-175.401.5822.21亿 8睿昂基因-100.21-82.271.4212.97亿9康泰医学-86.02-72.673.0756.61亿10中红医疗-69.48-55.420.8848.28亿 11华大智造-62.11-55.114.28331.13亿 来源：金融界 从行业 ...

智通财经5月15日电，迎丰股份(605055.SH)发布股票交易异常波动暨风险提示公告。截至2025 年5月15 日收盘，最新公司静态市盈率为92.72倍，换手率11.21%；根据中证指数有限公司发布的证监会行业市 盈率显示，公司所处的纺织业静态市盈率为23.81倍，公司静态市盈率高于同行业平均水平。此外，公 司2025年第一季度净亏损986.19万元，同比下降113.24%。经核实，公司不存在应披露而未披露的重大 信息。 五连板迎丰股份：市盈率高于同行业平均水平 不存在应披露而未披露的重大信息 ...

本文源自：金融界 作者：行情君 深圳中电港技术股份有限公司的主营业务是电子元器件分销、设计链服务、供应链协同配套和产业数据 服务。公司的主要产品是存储器、处理器、模拟器件、射频与无线连接。 最新一期业绩显示，2025年一季报，公司实现营业收入174.70亿元，同比49.01%；净利润8455.51万 元，同比64.99%，销售毛利率2.66%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)29中电港53.2960.782.71144.08亿行业平均 44.8869.382.9089.00亿行业中值34.4743.921.9473.85亿1三态股份-4253.28510.575.4973.36亿2天音控 股-768.76327.083.45102.00亿3凯瑞德-298.29-955.6734.9017.06亿4*ST沪科-199.16-203.1230.1311.54亿5赫 美集团-89.29-89.457.0539.08亿6利尔达-83.71-61.669.5166.49亿7南极电商-36.91-46.482.61109.98亿8跨境 通-17.38-16.899.4680.86亿9中成股份-16 ...

Core Viewpoint - Liao Port Co., Ltd. has a current stock price of 1.53 yuan, with a PE ratio of 37.46, which is significantly higher than the industry average of 14.05 and the median of 15.79, indicating potential overvaluation in comparison to peers [1][2] Company Summary - Liao Port Co., Ltd. operates in various logistics sectors, including oil products, container, automobile, bulk cargo, grain, and passenger roll-on/roll-off services, with a focus on port value-added and support services [1] - The company reported a revenue of 2.527 billion yuan for Q1 2025, reflecting a year-on-year decrease of 12.51%, and a net profit of 204 million yuan, down 45.09% year-on-year, with a gross margin of 22.86% [1] Industry Summary - The average PE ratio for the shipping and port industry is 14.05, with a median of 15.79, indicating that Liao Port Co., Ltd. is ranked 31st among its peers in terms of valuation [2] - The total market capitalization of Liao Port Co., Ltd. is 36.575 billion yuan, which is higher than the industry average market cap of 29.861 billion yuan [2]

Company Overview - Dongxing Medical's closing price on May 14 was 24.49 yuan, an increase of 2.08%, with a rolling PE ratio of 27.38, marking a new low in 37 days, and a total market capitalization of 2.453 billion yuan [1] - The company specializes in the research, production, and sales of surgical medical devices, with main products including endoscopic staplers, open staplers, stapler components, electric hydraulic surgical tables, shadowless surgical lights, and delivery beds [1] Financial Performance - In the first quarter of 2025, Dongxing Medical reported operating revenue of 78.1865 million yuan, a year-on-year decrease of 14.84%, and a net profit of 12.064 million yuan, down 39.35% year-on-year, with a gross profit margin of 44.40% [1] Shareholder Information - As of May 9, 2025, Dongxing Medical had 10,593 shareholders, a decrease of 35 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Comparison - The average PE ratio for the medical device industry is 49.84, with a median of 36.65, placing Dongxing Medical at the 61st position in the industry ranking [2]

Core Insights - Yuyue Medical's stock closed at 35.8 yuan, with a PE ratio of 20.26, marking a new low in 26 days, and a total market capitalization of 35.889 billion yuan [1] - The average PE ratio in the medical device industry is 49.84, with a median of 36.65, placing Yuyue Medical at the 47th position [1][2] - As of April 18, 2025, Yuyue Medical has 40,000 shareholders, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Company Overview - Yuyue Medical specializes in the research, manufacturing, and sales of medical devices, focusing on areas such as respiratory oxygen, diabetes care, infection control solutions, home electronic testing, in vitro diagnostics, emergency and clinical rehabilitation equipment [1] - The company owns several major brands, including "Yuyue," "Jiefuro," "Hua Tuo," "Jin Zhong," "An Er Iodine," "Primedic," and "Liuliu Vision," with significant brand value and advantages due to product performance and effective brand communication [1] Financial Performance - In Q1 2025, Yuyue Medical reported revenue of 2.436 billion yuan, a year-on-year increase of 9.17%, while net profit was 625 million yuan, reflecting a year-on-year decrease of 5.26%, with a gross profit margin of 50.30% [2] - The company's PE (TTM) is 20.26, with a static PE of 19.88 and a price-to-book ratio of 2.74 [2]

Group 1 - The core viewpoint of the article highlights that Innotech's stock closed at 31.5 yuan, down 1.25%, with a rolling PE ratio of 21.92 times and a total market capitalization of 4.298 billion yuan [1] - Innotech operates in the bioproducts industry, which has an average PE ratio of 57.79 times and a median of 38.07 times, placing Innotech at the 34th position in the industry ranking [1] - As of the first quarter of 2025, four institutions held shares in Innotech, with a total of 5.2561 million shares valued at 183 million yuan [1] Group 2 - Innotech's main business focuses on the research, production, and sales of POCT rapid diagnostic products, primarily targeting respiratory pathogen detection, while also covering areas such as reproductive health, digestive tract, and hepatitis testing [1] - The latest performance report for the first quarter of 2025 shows that Innotech achieved an operating revenue of 207 million yuan, a year-on-year decrease of 26.51%, and a net profit of 95.2897 million yuan, down 34.77%, with a gross profit margin of 83.12% [1]